Details of the Drug

General Information of Drug (ID: DMAT8CG)

Drug Name
Goserelin
Synonyms AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN)
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Estrogen-receptor positive breast cancer N.A. Approved [2]
Endometriosis GA10 Investigative [2]
Male breast carcinoma N.A. Investigative [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 1269.4
Logarithm of the Partition Coefficient (xlogp) -1.5
Rotatable Bond Count (rotbonds) 32
Hydrogen Bond Donor Count (hbonddonor) 17
Hydrogen Bond Acceptor Count (hbondacc) 16
ADMET Property
Absorption
The drug is rapidly absorbed following subcutaneous administration []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Elimination
20% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 5 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0405 micromolar/kg/day [5]
Vd
The volume of distribution (Vd) of drug is 44.1 +/- 13.6 L []
Chemical Identifiers
Formula
C59H84N18O14
IUPAC Name
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Canonical SMILES
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
InChI
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
InChIKey
BLCLNMBMMGCOAS-URPVMXJPSA-N
Cross-matching ID
PubChem CID
5311128
ChEBI ID
CHEBI:5523
CAS Number
65807-02-5
DrugBank ID
DB00014
TTD ID
D00BCG
VARIDT ID
DR00378
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [7]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [7]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Gene/Protein Processing [7]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Gene/Protein Processing [8]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Gene/Protein Processing [7]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Protein Interaction/Cellular Processes [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Leutinizing-hormone-releasing hormone (GNRH1) DTT GNRH1 2.23E-01 0.04 0.06
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Goserelin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Goserelin and Eribulin. Breast cancer [2C60-2C6Y] [10]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Goserelin and Lapatinib. Breast cancer [2C60-2C6Y] [10]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Tamoxifen. Breast cancer [2C60-2C6Y] [10]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Goserelin and Toremifene. Breast cancer [2C60-2C6Y] [11]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Goserelin and Bosutinib. Breast cancer [2C60-2C6Y] [10]
Coadministration of a Drug Treating the Disease Different from Goserelin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Goserelin and Ivosidenib. Acute myeloid leukaemia [2A60] [12]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Goserelin and Midostaurin. Acute myeloid leukaemia [2A60] [10]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Goserelin and Idarubicin. Acute myeloid leukaemia [2A60] [10]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Goserelin and Daunorubicin. Acute myeloid leukaemia [2A60] [10]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Goserelin and Oliceridine. Acute pain [MG31] [10]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Goserelin and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [10]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Tacrine. Alzheimer disease [8A20] [11]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Galantamine. Alzheimer disease [8A20] [11]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Rivastigmine. Alzheimer disease [8A20] [11]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Donepezil. Alzheimer disease [8A20] [11]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Goserelin and Metronidazole. Amoebiasis [1A36] [13]
Ranolazine DM0C9IL Moderate Increased risk of prolong QT interval by the combination of Goserelin and Ranolazine. Angina pectoris [BA40] [10]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Goserelin and Ivabradine. Angina pectoris [BA40] [10]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Goserelin and Bepridil. Angina pectoris [BA40] [11]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Goserelin and Dronedarone. Angina pectoris [BA40] [11]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Goserelin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [14]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [10]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Goserelin and Promazine. Appearance/behaviour symptom [MB23] [10]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Goserelin and Cilostazol. Arterial occlusive disease [BD40] [10]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Goserelin and Voriconazole. Aspergillosis [1F20] [10]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Goserelin and Posaconazole. Aspergillosis [1F20] [10]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Levalbuterol. Asthma [CA23] [15]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Terbutaline. Asthma [CA23] [16]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Pirbuterol. Asthma [CA23] [16]
Isoetharine DMITSEH Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Isoetharine. Asthma [CA23] [16]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Goserelin and Salbutamol. Asthma [CA23] [15]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Goserelin and Formoterol. Asthma [CA23] [16]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Goserelin and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [10]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [10]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Goserelin and Desipramine. Attention deficit hyperactivity disorder [6A05] [10]
Oxytocin DMDL27I Moderate Increased risk of prolong QT interval by the combination of Goserelin and Oxytocin. Autism spectrum disorder [6A02] [10]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Ofloxacin. Bacterial infection [1A00-1C4Z] [10]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [10]
Erythromycin DM4K7GQ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Erythromycin. Bacterial infection [1A00-1C4Z] [10]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Goserelin and Clarithromycin. Bacterial infection [1A00-1C4Z] [10]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Goserelin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [11]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Goserelin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [17]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Goserelin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [10]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Norfloxacin. Bacterial infection [1A00-1C4Z] [10]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Goserelin and Levofloxacin. Bacterial infection [1A00-1C4Z] [10]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Goserelin and Moxifloxacin. Bacterial infection [1A00-1C4Z] [18]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Goserelin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [10]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Goserelin and Telithromycin. Bacterial infection [1A00-1C4Z] [10]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Goserelin and Retigabine. Behcet disease [4A62] [10]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Goserelin and Grepafloxacin. Bronchitis [CA20] [17]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Goserelin and Sotalol. Cardiac arrhythmia [BC9Z] [11]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Goserelin and Dofetilide. Cardiac arrhythmia [BC9Z] [11]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Goserelin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [10]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [16]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [15]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [16]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [16]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [16]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Goserelin and Oxaliplatin. Colorectal cancer [2B91] [10]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Halothane. Corneal disease [9A76-9A78] [10]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Goserelin and Propofol. Corneal disease [9A76-9A78] [19]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Sevoflurane. Corneal disease [9A76-9A78] [10]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Goserelin and Probucol. Coronary atherosclerosis [BA80] [10]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Goserelin and Methadone. Cough [MD12] [11]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Goserelin and Clofazimine. Crohn disease [DD70] [10]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Goserelin and Mifepristone. Cushing syndrome [5A70] [11]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Goserelin and Pasireotide. Cushing syndrome [5A70] [11]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Goserelin and Osilodrostat. Cushing syndrome [5A70] [10]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Goserelin and Sertraline. Depression [6A70-6A7Z] [10]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Goserelin and Trimipramine. Depression [6A70-6A7Z] [10]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Imipramine. Depression [6A70-6A7Z] [10]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Goserelin and Fluoxetine. Depression [6A70-6A7Z] [10]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Nortriptyline. Depression [6A70-6A7Z] [10]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Goserelin and Escitalopram. Depression [6A70-6A7Z] [11]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Goserelin and Clomipramine. Depression [6A70-6A7Z] [10]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Trazodone. Depression [6A70-6A7Z] [10]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Goserelin and Amitriptyline. Depression [6A70-6A7Z] [10]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Goserelin and Amoxapine. Depression [6A70-6A7Z] [10]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Mirtazapine. Depression [6A70-6A7Z] [10]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Goserelin and Protriptyline. Depression [6A70-6A7Z] [10]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Goserelin and Doxepin. Depression [6A70-6A7Z] [10]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Goserelin and Maprotiline. Depression [6A70-6A7Z] [10]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Venlafaxine. Depression [6A70-6A7Z] [10]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Goserelin and Citalopram derivative 1. Discovery agent [N.A.] [11]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Goserelin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [10]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Goserelin and Deutetrabenazine. Dystonic disorder [8A02] [10]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Goserelin and Ingrezza. Dystonic disorder [8A02] [10]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Goserelin and Solifenacin. Functional bladder disorder [GC50] [10]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Goserelin and Pentamidine. Fungal infection [1F29-1F2F] [10]
Fluconazole DMOWZ6B Moderate Increased risk of prolong QT interval by the combination of Goserelin and Fluconazole. Fungal infection [1F29-1F2F] [10]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Goserelin and Ketoconazole. Fungal infection [1F29-1F2F] [10]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Goserelin and Cisapride. Gastro-oesophageal reflux disease [DA22] [11]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Goserelin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [10]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Goserelin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Goserelin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [20]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Goserelin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [21]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Goserelin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [10]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Polyethylene glycol. Irritable bowel syndrome [DD91] [10]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Phenolphthalein. Irritable bowel syndrome [DD91] [11]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Goserelin and Crizotinib. Lung cancer [2C25] [22]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Goserelin and Ceritinib. Lung cancer [2C25] [11]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Goserelin and Osimertinib. Lung cancer [2C25] [23]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Goserelin and Selpercatinib. Lung cancer [2C25] [10]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Goserelin and Lumefantrine. Malaria [1F40-1F45] [13]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Goserelin and Halofantrine. Malaria [1F40-1F45] [24]
Chloroquine DMSI5CB Moderate Increased risk of prolong QT interval by the combination of Goserelin and Chloroquine. Malaria [1F40-1F45] [10]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Goserelin and Hydroxychloroquine. Malaria [1F40-1F45] [10]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Quinine. Malaria [1F40-1F45] [10]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Goserelin and Primaquine. Malaria [1F40-1F45] [10]
Mefloquine DMWT905 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Mefloquine. Malaria [1F40-1F45] [10]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [10]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Goserelin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [25]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Goserelin and Vemurafenib. Melanoma [2C30] [11]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Goserelin and Panobinostat. Multiple myeloma [2A83] [26]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Thalidomide. Multiple myeloma [2A83] [13]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Goserelin and Siponimod. Multiple sclerosis [8A40] [13]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Goserelin and Fingolimod. Multiple sclerosis [8A40] [11]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Goserelin and Ozanimod. Multiple sclerosis [8A40] [27]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Goserelin and Romidepsin. Mycosis fungoides [2B01] [10]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Goserelin and Nilotinib. Myeloproliferative neoplasm [2A20] [11]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Goserelin and Dasatinib. Myeloproliferative neoplasm [2A20] [10]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Goserelin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [28]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Goserelin and Droperidol. Nausea/vomiting [MD90] [11]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Goserelin and Prochlorperazine. Nausea/vomiting [MD90] [10]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Goserelin and Promethazine. Nausea/vomiting [MD90] [10]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Goserelin and Palonosetron. Nausea/vomiting [MD90] [10]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Granisetron. Nausea/vomiting [MD90] [10]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Goserelin and Dolasetron. Nausea/vomiting [MD90] [11]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Goserelin and Ondansetron. Nausea/vomiting [MD90] [10]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Goserelin and Entrectinib. Non-small cell lung cancer [2C25] [10]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Goserelin and Levomethadyl Acetate. Opioid use disorder [6C43] [10]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Lofexidine. Opioid use disorder [6C43] [10]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Rucaparib. Ovarian cancer [2C73] [10]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Goserelin and Dextropropoxyphene. Pain [MG30-MG3Z] [10]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Goserelin and Buprenorphine. Pain [MG30-MG3Z] [10]
Tramadol DMRQD04 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Tramadol. Pain [MG30-MG3Z] [10]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Goserelin and Triclabendazole. Parasitic worm infestation [1F90] [10]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Goserelin and Pimavanserin. Parkinsonism [8A00] [10]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Apomorphine. Parkinsonism [8A00] [10]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Goserelin and Famotidine. Peptic ulcer [DA61] [13]
Vasopressin DMQ2FPC Moderate Increased risk of prolong QT interval by the combination of Goserelin and Vasopressin. Pituitary gland disorder [5A60-5A61] [10]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Goserelin and Macimorelin. Pituitary gland disorder [5A60-5A61] [29]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Goserelin and Lefamulin. Pneumonia [CA40] [30]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Ritodrine. Preterm labour/delivery [JB00] [16]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Goserelin and Alfuzosin. Prostate hyperplasia [GA90] [10]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Goserelin and Levomepromazine. Psychotic disorder [6A20-6A25] [10]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Goserelin and Fluphenazine. Psychotic disorder [6A20-6A25] [10]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Goserelin and Triflupromazine. Psychotic disorder [6A20-6A25] [10]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Goserelin and Sorafenib. Renal cell carcinoma [2C90] [10]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Goserelin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [18]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Goserelin and Quetiapine. Schizophrenia [6A20] [10]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Goserelin and Mesoridazine. Schizophrenia [6A20] [11]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Goserelin and Thioridazine. Schizophrenia [6A20] [11]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Goserelin and Aripiprazole. Schizophrenia [6A20] [13]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Goserelin and Iloperidone. Schizophrenia [6A20] [11]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Goserelin and Paliperidone. Schizophrenia [6A20] [10]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Goserelin and Haloperidol. Schizophrenia [6A20] [11]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Goserelin and Perphenazine. Schizophrenia [6A20] [10]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Chlorpromazine. Schizophrenia [6A20] [10]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Goserelin and Clozapine. Schizophrenia [6A20] [11]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Goserelin and Trifluoperazine. Schizophrenia [6A20] [10]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Goserelin and Ziprasidone. Schizophrenia [6A20] [11]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Goserelin and Risperidone. Schizophrenia [6A20] [10]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Goserelin and Olanzapine. Schizophrenia [6A20] [13]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Goserelin and Amisulpride. Schizophrenia [6A20] [31]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Asenapine. Schizophrenia [6A20] [10]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Goserelin and Pimozide. Schizophrenia [6A20] [10]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Vardenafil. Sexual dysfunction [HA00-HA01] [10]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Goserelin and LEE011. Solid tumour/cancer [2A00-2F9Z] [11]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Goserelin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [10]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Goserelin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [11]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Goserelin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [10]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Pitolisant. Somnolence [MG42] [10]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Goserelin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [10]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Goserelin and Ibutilide. Supraventricular tachyarrhythmia [BC81] [11]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Goserelin and Adenosine. Supraventricular tachyarrhythmia [BC81] [11]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Goserelin and Zithromax. Syphilis [1A61-1A6Z] [10]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Goserelin and Anagrelide. Thrombocytosis [3B63] [11]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Lenvatinib. Thyroid cancer [2D10] [10]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Goserelin and Cabozantinib. Thyroid cancer [2D10] [10]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Goserelin and Papaverine. Tonus and reflex abnormality [MB47] [32]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Goserelin and Tizanidine. Tonus and reflex abnormality [MB47] [10]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Goserelin and Tacrolimus. Transplant rejection [NE84] [10]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Goserelin and Astemizole. Vasomotor/allergic rhinitis [CA08] [10]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Goserelin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [10]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Goserelin and Disopyramide. Ventricular tachyarrhythmia [BC71] [11]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Goserelin and Procainamide. Ventricular tachyarrhythmia [BC71] [11]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Goserelin and Propafenone. Ventricular tachyarrhythmia [BC71] [10]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Goserelin and Flecainide. Ventricular tachyarrhythmia [BC71] [10]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Goserelin and Amiodarone. Ventricular tachyarrhythmia [BC71] [11]
⏷ Show the Full List of 186 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3879).
2 Goserelin FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
7 A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):94-103. doi: 10.1016/j.ejogrb.2006.07.042. Epub 2006 Sep 14.
8 [Kuntai capsule combined with gonadotropin releasing hormone agonist in treatment of moderate-severe endometriosis: a clinical observation]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1288-91.
9 Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. J Urol. 2006 Jul;176(1):354-60. doi: 10.1016/S0022-5347(06)00516-7.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 Canadian Pharmacists Association.
12 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
15 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
16 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
17 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
18 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
19 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
20 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
21 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
22 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
24 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
25 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
26 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
27 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
28 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
29 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
30 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
31 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
32 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]